

MARKET REPORT



Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2016

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2016

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** pdb@bioportfolio.co.uk

Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2016

Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, "Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2016" provides an overview of Relapsed Multiple Myeloma clinical trials scenario. This report provides top line data relating to the clinical trials on Relapsed Multiple Myeloma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment

- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Additional Details

Publisher : Global Data

Reference : GDHC3725CTIDB

Number of Pages : 486

Report Format : PDF

Publisher Information :



GlobalData »

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

Table Of Contents for Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2016 [Published by Global Data]

- Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Five Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Relapsed Multiple Myeloma Therapeutics Clinical Trials 27
Prominent Drugs 28
Latest Clinical Trials News on Relapsed Multiple Myeloma 29
Jul 28, 2016: AbbVie Announces Initiation of Phase 3 Study of Venetoclax in Patients with Relapsed or Refractory Multiple Myeloma 29
Clinical Trial Profile Snapshots 30
Appendix 483
Abbreviations 483
Definitions 483
Research Methodology 484
Secondary Research 484
About GlobalData 485
Contact Us 485
Disclaimer 485
Source 486

List Of Tables in Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2016 [Published by Global Data]

List of Tables

Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Region, 2016*	6
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016*	7
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016*	8
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016*	9
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016*	10
Relapsed Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries, 2016*	11
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016*	12
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016*	13
Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2016*	14
Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016*	15
Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016*	16
Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2016*	17
Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016*	18
Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016*	19
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase, 2016*	20
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase 2016*	21
Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2016*	22
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2016*	23
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015	24
Relapsed Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016*	25
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2016*	26
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016*	27
Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016*	28

List Of Figures, Charts and Diagrams in Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2016 [Published by Global Data]

List of Figures

- Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
- Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
- Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
- Relapsed Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
- Relapsed Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
- Relapsed Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
- Relapsed Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
- Relapsed Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13
- Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2016* 14
- Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
- Relapsed Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
- Proportion of Relapsed Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2016* 17
- Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
- Relapsed Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
- Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
- Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
- Relapsed Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
- Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
- Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
- Relapsed Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
- Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
- Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
- Relapsed Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

GlobalData Methodology 484

How to Buy...

Relapsed Multiple Myeloma Global Clinical Trials Review, H2, 2016 [Published by Global Data]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/27409>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at pdb@bioportfolio.co.uk or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$2500** | Single User Price
- \$5000** | Site License Price
- \$7500** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.